ER/PR IHC Markers

Function

The Estrogen Receptor (ER) and Progesterone Receptor (PR) Immunohistochemistry (IHC) markers are essential diagnostic tools used primarily in the management of breast cancer. These tests detect the presence of hormone receptors on the surface of cancer cells. When hormones like estrogen and progesterone bind to these receptors, they can stimulate the growth of the tumor.

Why it is Ordered

This test is standard practice following a breast cancer diagnosis. It helps oncologists determine the specific subtype of breast cancer and predict the tumor's likely response to hormone therapy. If a tumor is 'ER-positive' or 'PR-positive,' it means the cancer cells grow in response to these hormones, making the patient a candidate for targeted endocrine therapies.

Associated Conditions

• Hormone Receptor-Positive Breast Cancer: Indicates that the cancer is likely to respond to treatments that block hormone signals (e.g., Tamoxifen or Aromatase inhibitors).
• Triple-Negative Breast Cancer: Defined by the absence of ER, PR, and HER2 receptors. This subtype requires different treatment strategies, such as chemotherapy, as it does not respond to hormone therapy.
• Prognostic Assessment: Generally, ER/PR positive tumors are associated with a better prognosis and lower recurrence rates compared to receptor-negative tumors.

Therapeutic Impact

The results of the IHC markers directly dictate the therapeutic roadmap. Patients with positive markers are often prescribed long-term hormonal therapy to reduce the risk of recurrence. Understanding these markers is critical for personalized medicine in oncology.